Charts Week Month
Heat map Market Overview
Sentiment Sectors ETFs
Earnings News Earnings Movers The Drift Pivots
The Big Picture Breakouts Full Earnings News
Investor Services

Earnings are the driver of stock prices and the right earnings information can help longer-term investors significantly outperform the overall stock market.

The Whisper Report ® A look at upcoming earnings from both a top-down and bottom-up basis. Grades Stocks with A+ Earnings Whisper Grades Have Significantly Outperformed the Stock Market. Call Summaries Conference call summaries. AI Call Analysis AI Conference call analysis. Earnings Daily earnings results. Guidance Daily earnings guidance from companies. Reactions Earnings Screener Short Interest Report When the short trade becomes crowded.
Trader Service

Short-term earnings trading tools built around expectations, sentiment, quantitative studies, volatility, and post-earnings drift.

Trading Strategy The current strategy based on a broad market analysis and data. Earnings Whisper Plays Combining research, sentiment, quantitative studies, and technical analysis for short-term trades. Scores Identifying the likely Earnings Announcement Premium. Power Ratings Earnings with enough power for a short-term Post-Earnings Announcement Drift. Whisperings ^TM Whisperings are comments from analysts about upcoming earnings releases. AI Call Rankings Find which companies had the strongest or weakest conference calls. Option Trades Volatility Options Activity Unusual options activity around earnings. Setups Unusual options activity around earnings. Reversals Unusual options activity around earnings. Spikes Unusual options activity around earnings.
Dashboard

CRIS Curis, Inc.

-

Curis Beat Consensus Estimates

Friday, August 14, 2026 · 12:00 AM ET

Curis (CRIS) reported a loss of $4.02 per share on revenue of $0.00 million for the second quarter ended June 2026. The consensus estimate was a loss of $5.70 per share. The company beat consensus estimates by 29.47% while revenue fell 100.00% compared to the same quarter a year ago.

Curis Inc is a biotechnology company engaged in developing and commercializing drug candidates for the treatment of human cancers. Its products include CUDC-907, phosphatidylinositol-3-kinase and small molecule inhibitor of histone deacetylase.

Earnings Whisper Grade

Power Rating

Reported Earnings

($4.02)

Earnings Whisper^®

—

Consensus Estimate

($5.70)

Earnings Surprise

Earnings Growth

Reported Revenue

—

Revenue Estimate

—

Revenue Surprise

Revenue Growth